Literature DB >> 16182754

Long-term results of in situ split-liver transplantation.

U Baccarani1, G L Adani, A Risaliti, M Sainz-Barriga, D Lorenzin, P Chiarandini, D Montanaro, P Viale, G Della Rocca, F Bresadola.   

Abstract

BACKGROUND: Split-liver transplantation (SLT) offers immediate expansion of the cadaver donor pool. The principal beneficiaries have been adult and pediatric recipients with excellent outcomes. This study analyzed a single-center experience of adult to adult in situ SLT in adult recipients. PATIENTS AND METHODS: Fourteen consecutive adult-to-adult in situ SLT have been performed at our institution since 1998. The extended right lobe comprising segment 1 was transplanted in to adult patients, the left lateral segment, for pediatric transplants.
RESULTS: Donors of SLT were significantly younger (P = .03) than those of whole liver transplants. Survival rates of patients receiving a split liver were 83%, 73%, and 73% at 1, 3, and 5 years after the transplant respectively and grafts of 73%, 73%, and 73% for SLT and 76%, 70%, and 66% for whole liver transplants (P = .44). The rate of biliary complication after SLT was 21%, which was comparable to that after whole organ transplantation (17%). The incidence of hepatic artery thrombosis and primary nonfunction was not significantly different between split liver and whole organ transplantation performed during the same time period (7% versus 4.6% P = .67 and 7% versus 2.6% P = .32, respectively).
CONCLUSION: This limited single-center experience confirmed that both early and long-term results of SLT are comparable to those of traditional whole liver organ transplantation.

Entities:  

Mesh:

Year:  2005        PMID: 16182754     DOI: 10.1016/j.transproceed.2005.06.026

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  1 in total

1.  Fates of retained hepatic segment IV and its prognostic impact in adult split liver transplantation using an extended right liver graft.

Authors:  Yong-Kyu Chung; Shin Hwang; Chul-Soo Ahn; Ki-Hun Kim; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung; Gil-Chun Park; Young-In Yoon; Woo-Hyoung Kang; Hwui-Dong Cho; Jin Uk Choi; Minjae Kim; Sang Hoon Kim; Byeong-Gon Na; Sung-Gyu Lee
Journal:  Ann Surg Treat Res       Date:  2021-06-30       Impact factor: 1.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.